Lyra Therapeutics Inc (NASDAQ:LYRA) currently has a daily average trading volume of 3.27M but it saw 1342652 shares traded in last market. With a market cap of 6.12M USD, the company’s current market price of $0.09 came falling about -1.70 while comparing to the previous closing price of $0.09. In past 52 weeks, the stock remained buoying in the range of price level as high as $0.36 and as low as $0.08.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Jefferies which downgraded the stock as “Hold” in its note to investors issued on May 07, 2024, recommending a price target of between $10 and $0.50 for it. H.C. Wainwright downgraded its recommendation for the stock as a “Neutral” from “Buy” on May 07, 2024 while assigning a price target range of $12-$2.
Over the week, LYRA’s stock price is moving -18.09% down while it is -0.22% when we observe its performance for the past one month. Year-to-date it is -55.23% down and over the past year, the stock is showing a downside performance of -75.23%.
The company is expected to be releasing its next quarterly report in June, for which analysts forecasted an EPS of -0.1 while estimate for next year EPS is -0.42. In next quarter, company is expected to be making quarterly sales of $440k as analysts are expecting the sales for current fiscal year at $860.25k and seeing the company making $3.87M in sales next year. Moreover, analysts are in estimates of $440k for current-quarter revenue.
Currently, Lyra Therapeutics Inc’s total number of outstanding shares is 65.88M with 0.83% of that held by the insiders while 48.65% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -241.11% and return on equity (ROE) at -195.46%. Stock’s beta reads -0.01. Stock has a price to book (P/B) ratio of 1.57 while price to sale or P/S ratio amounts to 5.14. Its return on asset (ROA) is -80.40% on average.
